The short answer
A molecular tumor board is a meeting, not a test. Specialists review a biomarker report together and decide whether an approved drug, a trial, more testing, or standard care is the best next step.
A molecular tumor board reviews genomic test results that already exist; nothing new is drawn or scanned because your case went to one.
Membership usually spans pathology, radiology, medical oncology, genetic counseling and pharmacy, and varies by centre.
The FDA has approved a short list of tumour-agnostic drugs tied to a molecular feature rather than an organ, and NCI publishes the response rates behind each.
Common board outcomes are a matched approved drug, a clinical trial, more testing, or nothing actionable — the last is a real answer.
Choose how you want to understand this
The full explanation.
It is a meeting, not a test
Nothing gets drawn, scanned, or sent to a lab because your case went to a molecular tumor board. The lab work already happened. The board is the meeting where a group of clinicians sits with your genomic report and argues about what it means for you.
That distinction matters when the phrase shows up in your chart. Seeing it does not mean a new finding appeared. It means your oncologist wanted more than one brain on the interpretation.
Who is in the room
Membership varies by cancer center, and there is no single national roster. The roles usually pulled in are the ones the American Cancer Society lists on a cancer care team. A pathologist, who classifies disease from tissue and lab tests. A radiologist, who reads the imaging. A medical oncologist running drug treatment. A genetic counselor, who works out whether a gene change is inherited or confined to the tumor. A pharmacist, checking that a proposed drug is safe alongside everything else you take.
Larger centers add molecular pathologists, bioinformatics staff, and someone who knows the open clinical trials in the building.
What the report in front of them looks like
Not all biomarker testing is the same size, and the board needs to know which was ordered.
A single-biomarker test looks for one thing. A multigene panel looks at many at once. NCI gives Oncotype DX as an example, which analyzes 21 genes. Whole-exome and whole-genome sequencing go wider still.
Some testing is done on blood rather than tissue. NCI names two FDA-approved liquid biopsy tests, Guardant360 CDx and FoundationOne Liquid CDx. These read tumor DNA circulating in blood, which is useful when a biopsy is hard to repeat.
The finding that makes these boards worth holding
For most of oncology, the drug follows the organ. Breast cancer gets breast cancer drugs. A short list of approvals breaks that rule: the FDA cleared them for a molecular feature found in any solid tumor. NCI tracks them, with the response rates from the trials that earned the approval.
- MSI-H or dMMR tumors. Pembrolizumab produced a 39.6 percent response rate across five trials in 149 patients, in adults and children. Dostarlimab produced 41.6 percent in 209 patients, adults only.
- TMB-high tumors, meaning 10 or more mutations per megabase of DNA. Pembrolizumab produced 29 percent responses in 102 patients from KEYNOTE-158. FoundationOne CDx is the companion test.
- NTRK gene fusions. Larotrectinib, 75 percent in 55 patients. Entrectinib, 57 percent in 54 adults and 70 percent in 33 children. Repotrectinib, 58 percent in 40 patients who had not had a similar drug before.
- BRAF V600E. Dabrafenib with trametinib, 41 percent in 131 adults and 25 percent in 36 children.
- RET gene fusions. Selpercatinib, 44 percent in 41 patients.
- HER2 at IHC 3+. Trastuzumab deruxtecan, with response rates of 51.4, 52.9, and 46.9 percent across three DESTINY trials.
- FGFR1 rearrangement in certain myeloid and lymphoid neoplasms. Pemigatinib, 79 percent complete cytogenetic response in 28 patients.
Read the fine print on two of these. The BRAF approval excludes colorectal cancer. The RET figure comes from patients other than lung and thyroid cancer, which have their own separate approvals. Tumor-agnostic does not mean the organ stopped mattering.
Four things a board can conclude
It helps to know the possible outcomes before you ask what yours was.
- A matched approved drug exists. Either a tumor-agnostic approval above, or an off-label use of a drug approved elsewhere.
- A clinical trial fits. NCI-MATCH enrolled 1,201 people across 38 treatment arms, and about 60 percent of them had uncommon cancers. A pediatric version runs in parallel.
- More testing is needed first. The panel run may not have covered the gene in question, or the tissue may be too old or too scant.
- Nothing actionable. This is a real and common answer. It does not mean the testing was wasted, and it does not mean standard treatment stopped working.
Why a match is not a prescription
NCI is blunt about the limits, and these are the reasons a promising report can go nowhere.
Not every cancer cell carries the same biomarker. A matched drug may clear the cells that carry it and leave the ones that do not. People also process drugs differently, so the same target does not guarantee the same result.
A biomarker report is a snapshot. NCI notes that biomarkers change over time, which is why a result from a biopsy taken two years ago may no longer describe the cancer you have now.
Then there is payment. NCI states that Medicare and Medicaid cover some biomarker testing for advanced cancer, that private insurers want evidence the test changes care, and that tests considered experimental usually are not covered. A drug used off-label may be denied even when the biology fits.
What to ask after a board reviews your case
- Which test was run, and which genes did the panel actually cover?
- Was the sample fresh tissue, archived tissue, or blood?
- What did the board conclude, and was there disagreement?
- Is the recommendation an approved use, an off-label use, or a trial?
- Who is submitting the insurance authorization, and by what date?
- If nothing was actionable, is repeat testing worth doing later?
Ask for the board's note or summary to be released to your portal. It is part of your record.
Related pages
Start with Pathology Reports, Biomarker Testing and Precision Medicine, and Getting a Second Opinion.
Sources
- https://www.cancer.gov/about-cancer/treatment/types/agnostic-cancer-therapies-hp-pdq
- https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment
- https://www.cancer.gov/about-cancer/treatment/types/precision-medicine
- https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match
- https://www.cancer.org/cancer/preparing-for-treatment/cancer-care-team.html
Words to know
Tap any term to see what it means.
Common questions
Is a molecular tumor board a test?
No. It is a meeting. The lab work has already been done, and the board is where clinicians from different specialties read the genomic report together and work out what it means for your treatment.
Does it mean something new was found in my results?
Not necessarily. It usually means your oncologist wanted more than one specialty looking at the interpretation before a decision is made.
What can the board decide?
Broadly four things: that an approved drug matches your result, that a clinical trial fits, that more testing is needed first, or that nothing in the report is actionable. The last outcome is common and does not mean the testing was wasted.
If the report shows a target, will I get that drug?
Not automatically. NCI notes that not every cancer cell carries the same biomarker, that people process drugs differently, and that insurers may decline a test or an off-label drug they consider unproven.
Can I see what the board concluded?
Ask for the board's note or summary to be released to your portal. It is part of your record, and it is worth asking whether the group agreed.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Turn this topic into questions for your next appointment.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-07-21 what this meansLast updated: 2026-08-13Next planned review: 2027-07-21
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share